{"id":42623,"date":"2015-03-24T00:00:00","date_gmt":"2015-03-23T23:00:00","guid":{"rendered":"https:\/\/techma.bakertilly.es\/operaciones-biotecnologia-febrero-2015\/"},"modified":"2025-03-12T11:34:36","modified_gmt":"2025-03-12T10:34:36","slug":"operaciones-biotecnologia-febrero-2015","status":"publish","type":"post","link":"https:\/\/techma.bakertilly.es\/en\/operaciones-biotecnologia-febrero-2015\/","title":{"rendered":"Operations Biotechnology February 2015"},"content":{"rendered":"<address><span style=\"color: #000000;\">February 2015 has been an active month for the Biotech sector. Spanish venture capital has carried out large deals in both Spanish and foreign companies. In addition, there have also been <a href=\"https:\/\/techma.bakertilly.es\/en\/merger-and-acquisition-m-a\/\" target=\"_blank\">M&amp;A transactions<\/a> and <a href=\"https:\/\/techma.bakertilly.es\/en\/merger-and-acquisition-m-a\/\" target=\"_blank\">mergers and acquisitions<\/a> in the sector.<\/span><\/address>\n<p><!--more--><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"color: #3366ff;\"><strong>Risk capital operations<\/strong><\/span><\/p>\n<p><span style=\"color: #000000;\"><span style=\"text-decoration: underline;\"><a href=\"http:\/\/www.ysioscapital.com\/\" target=\"_blank\" rel=\"noopener\"><span style=\"text-decoration: underline; color: #000000;\">Ysios capital <\/span><\/a><\/span>leads a $8.7M investment in<span style=\"text-decoration: underline;\"> <span style=\"text-decoration: underline; color: #000000;\">Prexton Therapeutics<\/span><\/span>a Swiss company that is developing a treatment for the motor complications associated with Parkinson's disease. In addition to Ysios, <span style=\"text-decoration: underline;\"><a href=\"http:\/\/sunstone.eu\/\" target=\"_blank\" rel=\"noopener\"><span style=\"text-decoration: underline; color: #000000;\">Sunstone Capital <\/span><\/a><\/span>has also led the round.<\/span><\/p>\n<p><span style=\"color: #000000;\">\"The participation in Prexton Therauphethics is the first investment of its Ysios Biofund II fund, which in March made its second investment by entering into a new equity investment in Prexton Therauphethics. <span style=\"text-decoration: underline;\"><a href=\"http:\/\/www.aurabiosciences.com\/\" target=\"_blank\" rel=\"noopener\"><span style=\"text-decoration: underline; color: #000000;\">Aura Biosciences<\/span><\/a><\/span>The company is developing an innovative therapy for the treatment of ocular melanoma,\" says Diego Guti\u00e9rrez of<span style=\"text-decoration: underline;\"><a href=\"https:\/\/techma.bakertilly.es\/en\/\"><span style=\"text-decoration: underline; color: #000000;\"> Abra-Invest<\/span><\/a>.<\/span><\/span><\/p>\n<p><span style=\"color: #000000;\"><span style=\"text-decoration: underline;\"><a href=\"http:\/\/www.idenbiotechnology.com\/es\" target=\"_blank\" rel=\"noopener\"><span style=\"text-decoration: underline; color: #000000;\">Iden Biotech<\/span><\/a><\/span>founded in 2005 by the Carbohydrate Metabolism research group of the Institute of Agrobiotechnology of Navarra, has received a \u20ac4M round in which the following have taken part<span style=\"text-decoration: underline;\"><a href=\"http:\/\/www.sodena.com\/index.php\/es\/\" target=\"_blank\" rel=\"noopener\"><span style=\"text-decoration: underline; color: #000000;\"> Sodena<\/span><\/a><\/span>\u00a0 and <span style=\"text-decoration: underline;\"><a href=\"http:\/\/www.crbinverbio.com\/\" target=\"_blank\" rel=\"noopener\"><span style=\"text-decoration: underline; color: #000000;\">CRB inverbio<\/span><\/a>.<\/span> Iden Biotech identifies plant genes of agronomic value for crop improvement and develops products of biological origin to improve crop quality.<\/span><\/p>\n<p><span style=\"color: #000000;\">The aim of the round is to expand its research equipment and facilities in Navarra, as well as to advance several of its breeding and agrobiological development programmes.<\/span><\/p>\n<p><span style=\"color: #3366ff;\"><strong>Mergers and Acquisitions in biotechnology<\/strong><\/span><\/p>\n<p><span style=\"color: #000000;\"><span style=\"text-decoration: underline;\"><a href=\"http:\/\/nmc.ae\/\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #000000; text-decoration: underline;\">NMC Health<\/span><\/a><\/span> buy the Eugin Clinic in Barcelona, the leading in vitro fertilisation centre in Spain, to <\/span><br \/>\n<span style=\"color: #000000;\">for \u20ac143M. The sellers, in addition to ProA Capital, include some of Eugin's founders and management.<\/span><\/p>\n<p><span style=\"color: #000000;\">Vita 34, Europe's first private cord blood bank, has acquired the Spanish company Secuvita.<\/span><\/p>\n<p><span style=\"color: #000000;\">\"Vita 34 had already bought the majority stake in Secuvita 4 years ago and now with the full acquisition of the company, Vita 34 implements its commercial strategy in Secuvita,\" says Diego Guti\u00e9rrez.<\/span><\/p>\n<p><span style=\"color: #000000;\">In March, Vita 34 continued to be active in acquisitions, acquiring the assets of <span style=\"text-decoration: underline;\"><a href=\"http:\/\/vivocell.org\/\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #000000; text-decoration: underline;\">Vivocell,<\/span><\/a><\/span> Austria's largest private stem cell bank.<\/span><\/p>\n<p><span style=\"color: #000000;\"><span style=\"text-decoration: underline;\"><a href=\"http:\/\/www.sorianatural.es\/\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #000000; text-decoration: underline;\">Soria Natural<\/span><\/a><\/span>the leading company in the manufacture and sale of natural products, phytotherapy and organic food, has completed the purchase of the Madrid laboratory Homeolab. This acquisition, which began in August 2014, will allow them to expand their product catalogue to become a benchmark in the homeopathy market in Spain.<\/span><\/p>\n<p>&nbsp;<\/p>","protected":false},"excerpt":{"rendered":"<p>February 2015 has been an active month for the Biotech sector. Spanish venture capital has carried out large deals in both Spanish and foreign companies. In addition, mergers and acquisitions have also taken place in the sector.<\/p>","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[1751],"tags":[238],"sectores":[],"tipo-contenido":[2260],"class_list":["post-42623","post","type-post","status-publish","format-standard","hentry","category-adquisiciones-mas-relevantes","tag-biotecnologia","tipo-contenido-noticias"],"acf":[],"_links":{"self":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/posts\/42623","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/comments?post=42623"}],"version-history":[{"count":0,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/posts\/42623\/revisions"}],"wp:attachment":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/media?parent=42623"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/categories?post=42623"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/tags?post=42623"},{"taxonomy":"sectores","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/sectores?post=42623"},{"taxonomy":"tipo-contenido","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/tipo-contenido?post=42623"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}